Every major Meta update gets called transformative. Most are not. Andromeda is one of the rare exceptions.
The update has been documented in every advertising publication and rolled out across most ad objectives by October 2025. The marketing industry has spent the months since calling it the biggest shift in Meta advertising in a decade. For healthcare advertisers specifically, that framing is closer to accurate than usual, but the reasons are not the ones most coverage emphasizes.
The Hype Layer and the Substance Layer
Most Andromeda coverage treats the update as a creative revolution. The advice tends to land in the same place: produce more ads, refresh them more often, trust the algorithm. That advice is not wrong. It is just not specific to healthcare.
The substance layer, the one that matters for medical and dental practices, is different. Andromeda has changed the structural relationship between healthcare advertisers and Meta’s targeting system. To understand why, the historical context matters.
What Healthcare Advertisers Were Working Around
Healthcare advertising on Meta has always operated under restrictions that ecommerce, retail, and consumer brands never had to think about. Practices cannot target users based on health conditions, medical history, or any attribute that could imply protected health information. Lower-funnel conversion events for healthcare have been progressively restricted since early 2025, with Meta narrowing what bookings, appointments, or patient inquiries it will accept as optimization signals.
The practical reality before Andromeda: healthcare advertisers had a worse toolkit than other industries. The targeting parameters that ecommerce brands relied on to find their best customers were off-limits to providers. The conversion optimization events that ecommerce brands fed back to the platform were limited for medical sites. Healthcare advertisers competed on a tilted field, and most of them did not realize how tilted.
What Andromeda Has Changed
Andromeda’s shift from advertiser-defined audiences to creative-driven delivery has an effect that goes underdiscussed in mainstream marketing coverage. The targeting work that healthcare advertisers were not allowed to do manually is now work the system does on its own. The AI reads the creative, predicts who will respond, and routes the ad accordingly. The historic disadvantage of being a healthcare advertiser, the locked-out targeting toolkit, is meaningfully smaller than it was 18 months ago.
This does not mean restrictions have gone away. Conversion event limitations remain. Special-category status still applies. Landing pages and pixel configurations still need to handle protected health information correctly. The compliance layer is intact.
What has changed is the targeting layer underneath the compliance layer. Healthcare advertisers no longer need access to the targeting parameters they could never use. The system delivers on creative signal, and creative signal is something providers can fully control and improve.
What Providers Should Actually Do
The most useful posture for healthcare providers under Andromeda is the opposite of the panic some agencies have generated about the change.
Practices should invest in creative production at a higher rate than they have historically. Not more spend on the same ads, but more ads inside the same spend. Quantity, variation, and freshness matter more than they did. Practices used to running one or two ads should plan for a portfolio of five to ten, refreshed every two to four weeks.
Practices should also ask whether the partner managing their Meta campaigns has adjusted its operating model. Partners still optimizing for narrow audience tweaks instead of creative throughput are behind the curve. The signal of an adapted partner is straightforward: more creative output, less audience manipulation, more conversation about hooks and angles, less about lookalike percentages.
And practices should resist the temptation to evaluate Meta in isolation. Meta is a hybrid awareness-and-interest channel. Every impression builds brand familiarity. When Meta runs alongside NextGen TV™ on home television screens, the compounding effect is multi-screen brand saturation. Patients who see a practice on Meta and again on their living-room TV arrive at the search box already familiar with the brand. Evaluating Meta on last-click metrics alone underweights this dynamic.
The final practical shift worth naming is creative-clinical alignment. Strong Andromeda performance for healthcare comes from creative that reflects the actual practice, the actual provider, and the actual patient outcomes, not from stock dental footage or generic medical imagery. The system reads visual and narrative signals at a level of granularity that exposes generic creative. Practices investing in a steady cadence of authentic, practice-specific creative are getting more from the same ad spend than practices recycling stock-feeling material.
The Honest Read
Andromeda is genuinely consequential for healthcare advertising, but not for the reasons the algorithm-update headlines say. The change healthcare providers should care about is structural, not tactical. Meta’s AI has effectively closed part of the gap that special-category restrictions opened a decade ago. Providers who recognize the structural change and reorient creative production accordingly will outperform providers who do not. The tactical advice (more creative, faster refreshes, broader audiences) is downstream of that structural shift, and following the tactics without understanding the why tends to produce uneven results.
To talk through what a creative-first SmartReach™ approach looks like for a specific practice, schedule a discovery call with the DIGI Search team.
